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Abstract
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IMPORTANCE—Severe neuropsychiatric conditions, such as schizophrenia, affect distributed
neural computations. One candidate system profoundly altered in chronic schizophrenia involves
the thalamocortical networks. It is widely acknowledged that schizophrenia is a
neurodevelopmental disorder that likely affects the brain before onset of clinical symptoms.
However, no investigation has tested whether thalamocortical connectivity is altered in individuals
at risk for psychosis or whether this pattern is more severe in individuals who later develop fullblown illness.
OBJECTIVES—To determine whether baseline thalamocortical connectivity differs between
individuals at clinical high risk for psychosis and healthy controls, whether this pattern is more
severe in those who later convert to full-blown illness, and whether magnitude of thalamocortical
dysconnectivity is associated with baseline prodromal symptom severity.
DESIGN, SETTING, AND PARTICIPANTS—In this multicenter, 2-year follow-up, casecontrol study, we examined 397 participants aged 12–35 years of age (243 individuals at clinical
high risk of psychosis, of whom 21 converted to full-blown illness, and 154 healthy controls). The
baseline scan dates were January 15, 2010, to April 30, 2012.

Author Manuscript

MAIN OUTCOMES AND MEASURES—Whole-brain thalamic functional connectivity maps
were generated using individuals’ anatomically defined thalamic seeds, measured using restingstate functional connectivity magnetic resonance imaging.

Author Manuscript

RESULTS—Using baseline magnetic resonance images, we identified thalamocortical
dysconnectivity in the 243 individuals at clinical high risk for psychosis, which was particularly
pronounced in the 21 participants who converted to full-blown illness. The pattern involved
widespread hypoconnectivity between the thalamus and prefrontal and cerebellar areas, which was
more prominent in those who converted to full-blown illness (t173 = 3.77, P < .001, Hedge g =
0.88). Conversely, there was marked thalamic hyperconnectivity with sensory motor areas, again
most pronounced in those who converted to full-blown illness (t173 = 2.85, P < .001, Hedge g =
0.66). Both patterns were significantly correlated with concurrent prodromal symptom severity (r
= 0.27, P < 3.6 × 10−8, Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed).
CONCLUSIONS AND RELEVANCE—Thalamic dysconnectivity, resembling that seen in
schizophrenia, was evident in individuals at clinical high risk for psychosis and more prominently
in those who later converted to psychosis. Dysconnectivity correlated with symptom severity,
supporting the idea that thalamic connectivity may have prognostic implications for risk of
conversion to full-blown illness.
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Schizophrenia is characterized as a neurodevelopmental disorder of distributed brain
2
dysconnectivity, emerging from complex biological alterations that affect large-scale neural
3
4
systems. Its symptoms are correspondingly pervasive, leading to lifelong disability for
5
most patients and profound economic consequences. Understanding neural disturbances in
schizophrenia constitutes a critical research goal that necessitates identification of
pathophysiologic mechanisms and biomarkers that aid risk prediction. Growing
sophistication in non-invasive neuroimaging offers away to characterize large-scale neural
6 8
system disturbances in psychiatric illness – by studying low-frequency fluctuations in the
7
blood oxygenation level–dependent (BOLD) signal at rest (ie, via resting-state functional
connectivity magnetic resonance imaging [rs-fcMRI]). This technique is increasingly
applied to the study of neuropsychiatric conditions given its brief acquisition time, cost69
effectiveness, and reproducibility , based on the hypothesis that conditions such as
schizophrenia are brain disorders that affect exchange of information across large-scale
neural networks.
10 12

One such neural system, repeatedly implicated in schizophrenia, – involves
13
thalamocortical loops through which most neural computations flow. Thalamocortical
14
systems have been studied extensively in humans using noninvasive neuroimaging. Both
14
15 16
rs-fcMRI and structural diffusion studies in humans , revealed that the thalamus is
organized into parallel pathways that form information routes with the neocortex. This
property makes the thalamus an ideal starting point and a possible lens into large-scale
12 17
neural system disruptions in schizophrenia. ,
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Indeed, several groups have recently reported disrupted thalamocortical functional
10 12
connectivity in chronic schizophrenia. – However, schizophrenia is a neurodevelopmental
illness associated with brain abnormalities that likely occur before onset of all clinical
18
symptoms. Currently, it is unknown whether thalamocortical dysconnectivity emerges
exclusively in association with chronic illness or whether high clinical risk (CHR) and
subsequent longitudinal conversion to full-blown illness (CHR-C), as opposed to
nonconversion (CHR-NC), are also associated with functional thalamocortical disruptions. It
is vital to address this question for 3 reasons: (1) to elucidate how incipient pathophysiologic
stages of putative schizophrenia affect large-scale neural systems before full-blown
symptoms emerge; (2) to establish whether disruptions in thalamocortical connectivity could
provide viable neural markers associated with clinical risk before conversion; and (3) to
extend recent discoveries while bypassing typical confounds associated with chronic illness
(eg, years of medication exposure).

Author Manuscript

In this study, we examined resting-state thalamocortical connectivity in the North American
Prodromal Longitudinal Study (NAPLS) clinical high-risk sample. After obtaining baseline
images, we longitudinally studied 243 CHR patients (21 CHR-C patients and 222 CHR-NC
patients) and 154 healthy controls who were demographically similar to the clinical group.
We tested the following 3 questions: (1) “Is CHR associated with thalamocortical
dysconnectivity?” (2) “Is thalamocortical dysconnectivity more severe in CHR-C compared
with CHR-NC patients?” and (3) “Is thalamocortical dysconnectivity associated with
severity of psychotic symptoms at baseline?”

JAMA Psychiatry. Author manuscript; available in PMC 2016 June 03.
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Methods
Participants
Our final sample included 243 CHR individuals (21 in the CHR-C group and 222 in the
CHR-NC group) and 154 controls. All participants were recruited as part of the NAPLS 2
19
cohort and underwent rs-fcMRI at their baseline evaluations (eTable 1 in the Supplement).
The study protocol and consent form were reviewed and approved by the institutional review
boards at each of the 8 participating data collection sites (University of California, Los
Angeles, Emory University, Harvard Medical School, Zucker Hillside Hospital, University
of North Carolina, University of California, San Diego, University of Calgary, and Yale
University). All participants provided written informed consent. All recruitment, symptom
assessment, and longitudinal evaluation details are presented in eTable 1 in the Supplement.
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All participants were between 12–35 years of age with IQ >70, no history of central nervous
system disorders and no substance dependence in the past 6 months. The CHR sample met
the Criteria of Prodromal Syndromes (COPS) following assessment with the Structured
Interview for Prodromal Syndromes (SIPS) by experienced MA/PhD level clinicians.
Participants were excluded for current or past diagnosis with Axis I psychotic disorders,
including affective psychoses, as determined by the Structured Clinical Interview for the
Diagnostic and Statistical Manual of Mental Disorders-IV (SCID). Other co-morbid Axis I
diagnoses, such as mood or anxiety disorders, were not exclusionary provided they did not
account for the subject’s prodromal symptoms. There were no significant differences in
substance use, anxiety, or age between CHR subjects who converted and those who did not.
HCS were excluded if they met criteria for any prodromal syndrome, current or past
psychotic disorder, or Cluster A personality disorder. HCS were also excluded for family
history (first-degree relatives) of any disorder involving psychotic symptoms and for current
use of psychotropic medication.
Neuroimaging Data Acquisition
Neuroimaging was performed at 8 sites. Five sites (University of California, Los Angeles,
Emory University, Harvard University, University of North Carolina, and Yale University)
used Siemens-Trio 3-T scanners (Siemens), 2 sites (Zucker Hillside Hospital and University
of California, San Diego) used General Electric HDx Signa scanners (General Electric), and
1 site (University of Calgary) used a General Electric Discovery scanner (General Electric).
All neuroimaging and functional connectivity analyses followed prior work and best
20 21
practices in the clinical connectivity literature, , with details presented in the eAppendix
in the Supplement.

Author Manuscript

Seed-Based Functional Connectivity Analysis Based on Thalamic Anatomy
22

Our seed-based approach followed a prior study using anatomically defined thalamic
23 24
nuclei. In-house Matlab tools , were used to examine thalamus connectivity with all gray
matter voxels. We computed a seed-based thalamus correlation map by extracting mean time
series across all voxels in each participant’s bilateral thalamus (anatomically defined through
25 26
Freesurfer-based segmentation , ). This entire thalamic signal was then correlated with
each gray matter voxel, and the computed Pearson correlation values were transformed to
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Fisher z values using a Fisher r-to-z transformation, providing a map for each participant
that was entered into second-level analyses in which each voxel’s value represented its
connectivity with the whole thalamus (eAppendix in the Supplement). To examine betweengroup differences, all individual-subject maps were entered into appropriate second-level
tests (either independent samples t-test or 1-way ANOVA with three between-group levels
[CHR-NC, CHR-C, HCS]), which was computed within FSL’s Randomize tool with 10,000
permutations. Type I error correction was determined via threshold-free cluster enhancement
(TFCE) using a P <.01 as the statistical threshold.

Results
Association of Psychosis Risk and Thalamic Dysconnectivity

Author Manuscript
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We tested whether the risk of psychosis was associated with thalamocortical dysconnectivity
across the 21 participants in the CHR-C group, 222 participants in the CHR-NC group, and
the 154 participants in the control group (computed via 1-way analysis of variance with one
between-group factor). We took 2 approaches to testing this hypothesis: (1) at the wholebrain level without regional constraints (eFigure 1 in the Supplement) and (2) within regions
10 12
known to exhibit robust thalamocortical dysconnectivity in chronic schizophrenia –
(eFigure 2 in the Supplement). Although similar effects were apparent in both cases, the
whole-brain results did not survive type I error correction (eFigure 1 in the Supplement).
The a priori constrained analyses, however, revealed robust between-group differences best
described as increased connectivity between thalamus and bilateral sensory motor cortices
but decreased connectivity among the thalamus, prefrontal cortex (PFC), and cerebellum,
10 12
similar to prior qualitative and quantitative observations in chronic schizophrenia. – This
effect was more prominent in CHR-C patients (Figure 1 and Table). To further characterize
the effects, we extracted the mean thalamic functional connectivity from the identified
regions of interest, as well as the connectivity distributions across all voxels (Figure 1).
Results indicated a marked shift for the CHR-C patients across all regions of interest,
confirmed via formal effect sizes (ie, overall hyperconnectivity: t173 = 3.77, P < .001, Hedge
28
g = 0.88;overall hypoconnectivity: t173 = 2.85, P < .001, Hedge g = 0.66). Across areas,
the CHR-NC group was associated with an intermediate level of dysconnectivity between
the individuals in the CHR-C and control groups.

Author Manuscript

These results, however, were restricted within the a priori regions previously identified in
chronic schizophrenia, guaranteeing effects across similar regions. There may be attenuated
effects elsewhere that do not resemble prior schizophrenia results. To examine this
possibility, we computed 2 post hoc pairwise comparisons presented at lower thresholds,
allowing qualitative inspection (eFigure 5 in the Supplement). Results revealed consistent
patterns of increased connectivity around sensory motor cortices but reductions around PFC,
striatum, and cerebellum, which were also more prominent in the CHR-C group.
Finally, there is increasing emphasis on processing procedures in rs-fcMRI research because
certain procedures, specifically, global signal regression (GSR) (eAppendix in the
29
Supplement), may complicate between-group comparisons. The GSR is associated with
the removal of a mean brain signal from each voxel’s time series, the magnitude of which
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may differ among clinical conditions. To rule out GSR confounds, we repeated analyses
without GSR (eFigure 3 and eFigure 4 in the Supplement), which did not alter results.
Patterns of Thalamocortical Dysconnectivity and Shared Disturbances
The present effects highlight 2 dissociable patterns: hyperconnectivity centered on sensory
motor cortices and reductions in thalamo-prefrontal-cerebellar connectivity. These effects
12
12
may reflect separable alterations. Alternatively, as found in chronic schizophrenia, these
findings could constitute shared disturbances whereby individuals with most severe
thalamic-sensory perturbations also have the greatest thalamo-prefrontal-cerebellar
dysconnectivity. To test this hypothesis, we correlated the strength of connectivity from
regions with reduced thalamic connectivity with regions with increased thalamic
12
connectivity, explicitly following approaches in our prior work (Figure 2).

Author Manuscript

Across all participants, there was a highly significant negative relationship (N = 397, r =
−0.58, P < 4.1 × 10−38) between the 2 findings, which held for the CHR group (N = 242, r =
−0.53, P < 1.2 × 10−19): individuals with the most severe thalamic-sensory
hyperconnectivity had the greatest thalamo-prefrontal-cerebellar hypoconnectivity. This
pattern indicates that the 2 disruptions represent shared thalamocortical alterations,
12
consistent with schizophrenia findings.
Association Between Baseline Symptoms and Thalamic Dysconnectivity

Author Manuscript
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Next, to provisionally test the clinical significance of thalamic dysconnectivity, we examined
its association with symptoms. We examined the composite score using the Scale of
31
Prodromal Symptoms (SOPS; composite positive symptoms ) for 2 reasons. First, prior
12
work in chronic schizophrenia identified a significant association between positive
symptoms and thalamic-sensory-motor hyperconnectivity, providing strong a priori
predictions. Second, we sought to circumvent stringent type I error correction arising from
many exploratory comparisons. We correlated symptoms with connectivity measures
separately for areas with reduced vs increased thalamic connectivity (ie, aggregate signal
across yellow vs blue foci in Figure 1). We examined this association across all participants
32
to remain maximally powered and motivated by a Research Domain Criteria strategy
because low SOPS scores may exist even in the general population (eTable 1 in the
Supplement). We identified a significant negative correlation between regions with thalamic
hypoconnectivity and symptoms (r = −0.31, P < 9.54 × 10−10, Spearman ρ = −0.32, P < 1.36
× 10−9, 2-tailed), which also held when we restricted analyses to those individuals who
presented with symptoms (r = −0.21, P < .001, Spearman ρ = −0.22, P < .001, 2-tailed) and
only to CHR patients (r = −0.14, P = .03, Spearman ρ = −0.32, P = .04, 2-tailed; eFigures 6
and 7 in the Supplement). There was also a significant positive correlation between SOPS
scores and hyperconnectivity across participants (r = 0.21, P < 4.1 × 10−5, Spearman ρ =
0.21, P < 4.8 × 10−5 ; Figure 3), which did not survive when we restricted the analysis to
symptomatic participants or CHR patients (eFigure 7 in the Supplement). To confirm that
the 2 disturbances are related, we calculated the difference in magnitude of
hyperconnectivity vs hypoconnectivity for each participant (ie, difference in connectivity for
yellow vs blue foci in Figure 1). We correlated the magnitude of this connectivity difference
with symptoms, which also revealed a significant association (r = 0.27, P < 3.6 × 10−8,
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Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed), which held when we restricted analyses to
those individuals who presented with symptoms (r = 0.17, P < .001, Spearman ρ = 0.14, P
< .001, 2-tailed) but did not survive when restricted to CHR patients (eFigure 7 in the
Supplement). Of note, we did not identify a significant association between identified
thalamic dysconnectivity and SOPS scores at the 2-year follow-up.
Association Between Medication and Thalamic Dysconnectivity

Author Manuscript

Last, we tested whether identified thalamic dysconnectivity was related to medication dose
and/or status. We first correlated medication level (calculated via chlorpromazine
33
equivalents ) with magnitude of thalamic hyperconnectivity and hypoconnectivity. This
analysis revealed no significant association, although there were modest trends (thalamic
hyperconnectivity: r = 0.19, P = .19; thalamic hypoconnectivity: r = −0.2, P = .16; n = 50
medicated patients). These trends imply that individuals who received higher doses of
medication had greater thalamocortical dysconnectivity at baseline. Next, we tested whether
effects differed as a function of medication status (because some individuals were medicated
34
even at their baseline scans ) (Figure 4). This analysis revealed that unmedicated patients in
the CHR-Cgroup (n = 17) exhibited the most profound thalamic-sensory-motor
hyperconnectivity (Figure 4), which significantly differed from the controls (t169 = 3.7, P < .
001, 2-tailed, Hedge g = 0.81). This effect is the opposite of what one would expect if a
medication confound were driving thalamic hyperconnectivity because medicated
individuals had a milder profile. Medicated and unmedicated patients in the CHR-C group
exhibited thalamic hypoconnectivity of similar magnitude (Figure 4). Again, the
unmedicated patients in the CHR-C group significantly differed from the controls (t169 =
2.34, P = .02, 2-tailed, Hedge g = 0.31). These secondary medication analyses rule out the
possibility that medication is driving the observed patterns.

Author Manuscript

Discussion
17 35
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Thalamic circuits feature prominently in theoretical models of schizophrenia , and are
10 12
implicated in empirical schizophrenia studies. – However, patterns of thalamic
dysconnectivity before full-blown illness conversion remain unknown. To address this
knowledge gap, we used rs-fcMRI to characterize thalamocortical dysconnectivity in
association with clinical risk and future conversion to full-blown psychosis. We identified
10 12
patterns consistent with recent discoveries in schizophrenia – : increased thalamic
connectivity with sensory motor cortices but reduced thalamic connectivity with PFC and
cerebellum, a pattern more prominent in CHR-C patients. Both patterns were modestly
correlated with symptoms and were observed in unmedicated individuals in the CHR group.
Results were observed during baseline imaging before psychosis onset, indicating that these
disturbances predate full-blown illness.
Risk for Psychosis and Thalamocortical Dysconnectivity
36 37

Schizophrenia is a neurodevelopmental disorder associated with genetic risk factors. ,
However, indicators of its emerging pathophysiologic conditions remain poorly understood,
with few viable neural markers that predict illness development and subsequent frank onset.
This lack of at-risk endophenotypes for schizophrenia is compounded by the scarcity of
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well-established neural markers of chronic illness. The field has made progress in defining
neural markers of cortical and subcortical dysfunction in schizophrenia through a
38 40
41
combination of postmortem – and neuroimaging studies examining structure, task42–46
21,47
based activation,
and functional and structural connectivity.
This work has been
enriched by resting-state studies mapping large-scale network disturbances in
48
schizophrenia : during the past year, several groups independently replicated prominent
10 12
thalamocortical disturbances in chronic schizophrenia. – Although promising, this work
has not addressed 2 vital questions. First, “Are the observed thalamocortical connectivity
disturbances in part related to long-term medication effects?” Second, from a clinical
standpoint, “Are these thalamocortical connectivity disturbances an exclusive feature of
long-standing illness, or do they emerge during early illness stages?” The second question is
particularly important for identifying neural markers that appear before progression to
chronic illness.

Author Manuscript
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We found that thalamocortical dysconnectivity was present in the CHR state before fullblown psychosis. The effects followed previously reported hyperconnectivity with sensory
motor areas and hypoconnectivity with PFC and cerebellum (note that hyperconnectivity
with other auditory and visual sensory regions was evident, although these regions did not
survive more stringent thresholding). Both patterns were more severe for CHR-C patients,
suggesting pathophysiologic relevance to the pathogenic cascade that culminates in
psychosis. These effects address the limitations of prior long-term studies: because thalamic
dysconnectivity in CHR patients closely mirrors effects reported in patients with chronic
illness and these patterns were observed in unmedicated patients, it is unlikely that these
alterations are driven by long-term pharmacotherapy. However, our analyses provisionally
imply that medication may exert a beneficial effect by reducing thalamocortical
hyperconnectivity.
Follow-up analyses revealed similar effects even at lower statistical thresholds (Figure 2).
Furthermore, thalamic hyperconnectivity and hypoconnectivity were highly related across
participants, suggesting a common system-wide disturbance (as reported in chronic
10 12
schizophrenia – ). Finally, the magnitude of thalamic dysconnectivity in both
hyperconnected and hypoconnected regions predicted symptoms. The difference in
magnitude between hyperconnectivity and hypoconnectivity also correlated with symptoms,
supporting the hypothesis that the 2 effects constitute a shared, system-wide thalamic
abnormality. By linking thalamic dysconnectivity with symptom levels before illness onset,
these results raise the question of whether thalamic dysconnectivity relates to genetic risk
and/or appears in unaffected relatives or whether it only emerges in association with
symptom expression (because patients in the CHR group were seeking help).

Author Manuscript

Although this study focused on the thalamus, other groups documented abnormalities across
49
9 50 52
striatal and cortical networks during CHR states or in patients with chronic illness. , –
Therefore, thalamocortical dysconnectivity cannot be construed as the only disturbance that
49
occurs during this at-risk period. For instance, Fornito and colleagues reported changes in
frontostriatal circuits that were strikingly similar to reported thalamic effects: a prominent
dorsal-to-ventral gradient of hypoconnectivity to hyperconnectivity between the striatal and
50
PFC regions, which correlated with symptoms. Baker and colleagues reported functional
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connectivity disruptions in associative cortices in patients with chronic illness, which may be
30
related to abnormal BOLD signal variance in these same associative networks. It is unclear
3
whether these disparate effects possibly reflect common upstream mechanisms (eg,
disrupted glutamate signaling or microglial alterations) or whether they constitute separable
53 54
abnormalities that emerge at distinct illness stages. , Longitudinal and genetic studies are
needed to map risk- and disease-related connectivity changes in relation to these emerging
neuroimaging markers. Such efforts will help disambiguate which markers relate to genetic
risk, early-course prodromal symptoms, frank illness onset, and, ultimately, chronic illness
effects, informing therapeutic design for specific illness phases. Finally, although these
effects are potentially compelling, the relatively small sample of converters limits firm
conclusions about whether this particular imaging phenotype is a true clinical predictor of
conversion.

Author Manuscript

Implications for the Neurobiology of Schizophrenia Onset

Author Manuscript

Present findings are correlational given the indirect neuroimaging measure (BOLD fcMRI)
and therefore cannot address upstream causal mechanisms. To map such upstream cellular
55
mechanisms, translational research from animal experiments, experimental pharmacologic
56
neuroimaging studies, and computational models can generate mechanistic and testable
17,30,57,58
predictions.
Schizophrenia likely involves alterations in glutamatergic,
dopaminergic, and inhibitory gamma-aminobutyric acid (GABA)
3 38 39 59 62
neurotransmission. , , , – Theoretical models of the illness repeatedly implicate these
neurotransmitter systems in thalamo-striatal-cortical circuits, which may contribute to the
observed alterations. It currently remains unknown which upstream mechanisms and at
which locus (subcortical or cortical) produce such widespread thalamic dysconnectivity. One
63
possibility may involve dysfunction of the N-methyl-D-aspartate glutamate receptor,
38 39 62
hypothesized to occur in inhibitory interneurons, , , which affects the balance of neural
64
excitation and inhibition in cortical circuits, producing brain-wide disturbances in
thalamocortical information flow.
Limitations

Author Manuscript

Although medication effects were largely ruled out, some CHR patients were medicated.
Thus, we correlated medication levels with magnitude of thalamocortical dysconnectivity,
which did not reveal significant effects. Furthermore, we compared medicated and
unmedicated CHR patients: although hypoconnectivity did not vary as a function of
medication status, the hyperconnectivity profile was actually worse for unmedicated CHR
patients, suggesting that medication did not drive primary effects. Another concern, present
in all clinical connectivity studies, relates to head movement. We used careful movementcensoring methods for all data and used movement (percentage of frames scrubbed) as a
covariate in the analysis, which did not alter effects (eAppendix in the Supplement).
Movement levels did not significantly differ between CHR-NC and CHR-C patients (Table),
increasing confidence that head movement did not drive effects. The data were pooled from
multiple sites and scanners, introducing possible scanner bias and other site-specific effects
on cohort recruitment and assessment. To mitigate this concern, we conducted 2 analyses:
we confirmed that results remained despite using site as a covariate in the reported analysis
(of note, there was a slight deviation from expected proportions revealed by a χ2 test; eTable
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2 in the Supplement). Another issue relates to the definition of risk; here, we studied
individuals who were clinically symptomatic and seeking help and therefore presented with
clinical elevated risk for psychosis conversion. Consequently, these findings cannot directly
address whether genetic liability for schizophrenia is associated with the same pattern of
thalamic dysconnectivity. We observed reported effects within a priori masks exhibiting
12
thalamocortical dysconnectivity in our prior work but not at the whole-brain level. This
finding may reflect restricted power because of the relatively smaller CHR-C group but also
the possibility that the CHR state may be associated with weaker effects relative to the more
12
robust patterns found in patients with chronic illness. In addition, although starting from
the entire thalamus may be a well-justified first-pass approach (to remain sensitive to panthalamic disruptions), there may be important discrepancies across thalamic subnuclei that
10 65
the current analysis did not consider. ,
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Conclusions
This study establishes that thalamocortical dysconnectivity is present in CHR states before
psychosis onset. We found that sensory motor and prefrontal-cerebellar thalamic
dysconnectivity was more severe in the CHR-C patients. These effects are congruent with
recent discoveries in patients with chronic illness, suggesting that brain-wide
thalamocortical dysconnectivity is apparent even during incipient illness stages and may
provide a sensitive marker for elevated clinical risk of full illness onset.
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Figure 1. Regions With Between-Group Differences in Thalamic Connectivity

Significant between-group effects were found for 5 regions of interest (ROIs) after a 1-way
27
analysis of variance F test using cluster protection after 10 000 permutations (see
Methods). Results were visualized using surface-based and volume maps. All displayed foci
revealed significant between-group effects within the thalamocortical masks identified in our
12
prior work (in which patients with chronic illness exhibited robust thalamocortical
disruptions; eAppendix and eTables 3 and 4 in the Supplement). Blue and yellow areas
indicate regions where the F test is driven by a reduction or increase, respectively, in
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thalamic connectivity in the clinical high risk for psychosis (CHR) groups. Magnitudes (left)
and distributions (right) across groups for each of the identified regions qualitatively
illustrate the direction of the effect. Effect sizes (Hedge g [Hg]) reflect the shift for the CHR
converted to full-blown illness (CHR-C) group relative to controls. For a complete list of
regions and statistics, see the Table. We used the Hg as a measure of effect size to account
for differences in sample size between the CHR-C and CHR-nonconversion (CHR-NC)
28
groups. Error bars indicate ±1 SEM. The histograms are based on the data extracted from
the F map presented in the surface view panel. We present reduced-threshold pairwise
effects in the eAppendix in the Supplement. L indicates left; and R, right.
a P < .01.
b P < .001.
c P < .05.
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Figure 2. Association Between Thalamic Hyperconnectivity and Hypoconnectivity Across Study
Participants

Author Manuscript

Regions with reduced (blue) and increased (yellow) thalamic connectivity (Figure 1). A
significant negative association is evident across all participants, collapsing across all 3
samples (r = −0.58, P < 4.1 × 10−38). Vertical/horizontal green dashed lines mark the zero
points. Patients with clinical high risk of psychosis (CHR) who converted to full-blown
illness (CHR-C) had a shift across the zero lines, indicative of weaker prefrontal-cerebellarthalamic connectivity but stronger sensory-motor-thalamic connectivity. Patients with CHR
who did not convert (CHR-NC) had a more intermediate degree of disruption, suggesting a
gradient (inset arrow for qualitative illustration). Ovals for each group mark the 95%CI. L
indicates left; and R, right.
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Figure 3. Association Between Prodromal Schizophrenia Symptoms and Thalamic
Dysconnectivity
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Regions showing reduced (blue) and increased (yellow) thalamic connectivity. Significant
positive association was found between thalamic connectivity across all areas showing
increased connectivity (yellow regions) and composite positive symptoms on the Scale of
Prodromal Symptoms (SOPS) across all participants (r = 0.21, P < 4.1 × 10−5, Spearman ρ =
0.21, P < 4.8 × 10−5). A significant negative association was found between thalamic
connectivity across all areas showing reduced connectivity (blue regions) and composite
positive symptoms on the SOPS across all participants (r = −0.31, P < 9.54 × 10−10,
Spearman ρ = −0.32, P < 1.36 × 10−9, 2-tailed). We computed a difference score between the
regions showing hyperconnectivity (yellow) and hypoconnectivity (blue). The purpose of
this calculation was to establish that the total magnitude of connectivity disruptions in either
direction still relates to psychotic symptoms as opposed to these 2 patterns capturing
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independent sources of variability. We found a significant association between thalamic
connectivity difference score and composite positive symptoms on the SOPS across all
participants (r = 0.27, P < 3.6 × 10−8, Spearman ρ = 0.27, P < 4.75 × 10−5, 2-tailed). For a
figure presenting clinical high risk (CHR) patients only, see eFigure 7 in the Supplement.
CHR-C indicates clinical high risk of psychosis converted to full-blown illness; CHR-NC,
clinical high risk of psychosis not converted to full-blown illness; L indicates left; and R,
right.
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Figure 4. Thalamic Dysconnectivity as a Function of Medication Status
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Regions with reduced (blue) and increased (yellow) thalamic connectivity, driven by the
clinical high risk of psychosis (CHR) converted to full-blown illness (CHR-C). The
association between medication status and thalamic hyperconnectivity indicated that CHR-C
patients who remained unmedicated (CHR-C-UM) exhibited the most severe
hyperconnectivity, significantly differing from controls (t169 = 3.7, P < .001, 2-tailed, Hedge
g = 0.81) and CHR patients who did not convert (CHR-NC) without medication (CHR-NCUM) (t190 = 2.27, P = .02, 2-tailed, Hedge g = 0.53). However, no significant difference was
found between medicated (CHR-C-M and CHR-NC-M) and CHR-C-UM and CHR-NC-UM
patients (t19 = 0.46, P = .76). Again, CHR-C-UM patients exhibited significant reductions in
thalamic connectivity with prefrontal cortex and cerebellar nodes relative to controls (t169 =
2.34, P = .02, 2-tailed, Hedge g = 0.31) but not the other clinical groups. We used Hedge g
28
as a measure of effect size to account for differences in sample sizes. Error bars indicate
±1 SEM. L indicates left; and R, right.
a P < .001.
b P < .05.
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